We performed a novel phase Ib clinical trial of adjuvant, p53 peptide-loaded dendritic cell (DC) based adjuvant vaccination for head and neck cancer patients. To the best of our knowledge this is the largest clinical trial experience of a DC-based cancer vaccine for these patients. With the recent FDA approval of cellular and antibody-based immunotherapeutic strategies, and the confirmation the TP53 alteration as the major genomic abnormality in head and neck cancer, we believe that our study of adjuvant p53-based vaccination is timely and valuable to warrant further phase II testing. In particular, our observation of consistent declines in regulatory T cells (Treg) in vaccinated patients, which are a poor prognostic subset of T cells, suggests that clinical benefit would result in larger vaccinated cohorts.
Introduction
Despite considerable recent advances in therapy of HNSCC, survival has not improved >50% for decades, largely due to tumor recurrence, high frequency of second primary tumors, development of distant metastases and resistance of the tumor to chemo-radiotherapy (1) . Novel therapeutic strategies are needed, and tumor antigen-specific vaccination has been perceived as a potentially effective approach to improve outcome by mobilizing anti-tumor immunity and reversing immune escape in HNSCC patients. Immune suppressive mechanisms described in these patients are extensive and include impaired dendritic cell (DC) maturation (2, 3), inefficient antigen presentation (4) , and an increased frequency as well as suppressive activity of regulatory T cells (Treg) (5) . As a result of HNSCC-induced immune suppression, anti-tumor responses of patients are compromised, and a reversal or removal of immune suppression would be expected to restore these responses. Consequently, anti-tumor vaccines offer an opportunity for normalization of immune responses and of the immune balance responsible for the control of tumor progression.
In all anti-tumor vaccines, the selection of a target antigen is one of the most critical issues. The requirements for the selection of a tumor associated antigen (TA) to be used in the vaccine have been defined (6) . Such a TA should be selectively expressed in the tumor cells but not normal tissues, naturally processed and presented by APC and immunogenic, i.e., able to induce TA-specific effector and helper T cells. Based on previous studies, p53 meets these criteria: it is the most frequently mutated gene in HNSCC (7) and the mutated protein accumulates in most HNSCC cells (8) , allowing for overexpression and processing of wt p53 peptides (8) (9) (10) (11) . We have previously demonstrated that the presentation of wt p53 peptides on DC induced peptide-specific immune responses in vitro in normal donors and in HNSCC patients (8, (12) (13) (14) . Similar in vivo studies with wt p53-pulsed DC in animal tumor models have also led to the development of anti-tumor immunity and inhibited tumor growth (11) . Also, DCbased wt p53 peptide vaccines have been used for immunotherapy of human ovarian, breast, lung and colon cancers (15) .
Here, we report the results of a phase Ib trial of autologous monocyte-derived DC loaded with selected wt p53 peptides. Although the study follows the design used for other wt p53-based DC vaccines (15, 16) , it includes several novel aspects. First, to determine whether the addition of T helper (Th) peptides to the vaccine results in the improvements of TA-specific anti-tumor
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Author Manuscript Published OnlineFirst on February 28, 2014; DOI: 10.1158/1078-0432.CCR- immunity, we included the HLA class II p53 helper peptide (p53 110-124 ref. (17) ) or tetanusderived memory peptide (18) in separate vaccine arms. Second, we used two altered (optimized) HLAA*0201 binding p53 peptides (p53 149-157 T150L variant, ref. (9) and p53 246-272 F270W variant, ref. (19) ) to enhance the peptide binding to TCR or to HLA-A2.1 with higher avidity, respectively. Third, serial immune monitoring of all vaccinated patients allowed for the consideration of TA-specific immunity generated in response to the vaccine in the context of clinical outcome. Finally, in vitro generation of DC from the patients' monocytes in parallel, comparing properties of DC used in the vaccine (vDC) with an alternative maturation protocol (DC1, (20, 21) ), allowed for the identification of improvements in the DC maturation that can boost their adjuvant activity in future trials. The study provides novel insights into optimization of the production and monitoring of adjuvant DC-based vaccines for patients with HNSCC and other p53-overexpressing epithelial malignancies.
Materials and Methods
Patient cohort. 16 HLA-A2.1 + patients with advanced HNSCC were enrolled in this study. Six patients were treated with surgery alone and 10 patients had received adjuvant chemoradiotherapy (CRT) after surgery. At the time of vaccination, all patients were free of disease.
The patients' clinical and demographic data are listed in Table I . All patients were treated at the University of Pittsburgh Cancer Institute and signed written informed consent to participate in this trial, which was approved by the Institutional Review Board of the University of Pittsburgh (UPCI 03-156; IRB# 0507062, NCT00798655), under FDA IND #12273 (sponsor RLF).
Immunohistochemistry of tumors for p53. Staining was performed with p53 monoclonal primary antibody (D011, 1:400 dilution) and secondary antibody 'Dual Envision Polymer,' using Antigen Retrieval-Citrate pH6 buffer (Dako, USA) and DAB chromogen (Dbiosys, CA, USA). p53 protein accumulation was scored as positive when >10% of tumor cells were stained positive as observed by the study pathologist.
Generation of DC.
Monocytes were isolated from autologous leukapheresis products by the Elutra System (Caridian BCT, CO). The monocyte-rich fraction #5 was collected and analyzed for cell viability, cell counts and the cell phenotype by flow cytometry. Following 6-day culture containing 10,000 harvested iDC were re-plated in T-75 culture flasks in medium containing GM-CFS and IL-4 as above, and matured by the addition of a pro-inflammatory cytokine cocktail for 48h. DC used for vaccination of patients (vDC) were matured in a cytokine cocktail containing IL-1β (10ng/mL), IL-6 (10ng/mL), TNF-α (10ng/mL) and PGE 2 (1ug/mL), The maturation cytokine cocktail for DC1, which were generated in parallel with vDC but were not used for vaccination, contained IL-1β (10ng/mL), TNF-α (50ng/mL), IFN-α (3,000IU/mL), IFN-γ (1,000IU/mL) and Poly I:C (20ug/mL). Supernatants of both DC preparations were collected for cytokine measurements (IL-10, IL-12, VEGF) by Luminex (22) . In Arm 2, the modified, pan-DR binding T-helper epitope from tetanus toxoid (AQYIKANSKFIGIGL, (18, (23) (24) (25) ) was used. HLA DR4 -patients were randomized to Arm 1 (no helper peptide) or Arm 2 (tetanus helper peptide). All HLA-DR4 + patients were assigned to Arm 3 due to DR4 + restriction of the Th p53 110-124 peptide sequence (26) .
Fresh or cryopreserved mDC were loaded with the respective combinations of class I / class II peptides (10uM each) for 18h. Autologous DC (100 uL) were injected into an inguinal lymph node (LN) under ultrasound guidance biweekly for three time points. The vaccination schedule and the injection site were selected based on previously reported successful experience at our institution (27, 28) . LN in the head and neck region were avoided, as they could have been affected by the proximity of tumor cells. Antibodies and flow cytometry. The following anti-human monoclonal antibodies (mAb) were used for staining CD3-FITC, CD4-PC5, CD8-PC5, CD14-ECD, CD80-FITC, CD86-PE, DR-ECD, CD83-PC5, CD1a-PC5 (Beckman Coulter), HLA-A2-PE (Biolegend), CCR7-FITC (R&D Systems), CD39-FITC, (eBioscience), CD25-PE (Miltenyi), including their respective isotypes, which served as negative controls for surface as well as intracellular staining. All Abs were pretitrated using PBMC to determine the optimal staining dilution for each. For HLA-typing and determination of APM components we used BB7.2 δ-specific mAb SY-4, LMP 2-specific mAb SY-1, TAP1-specific mAb, TAP2-specific mAb NOB-2, tapasin-specific mAb TO-3 which were generated by Dr. Soldano Ferrone (Harvard U) and generously donated for these studies (3).
Cryopreserved cells were thawed and washed in RPMI medium. For flow cytometry, cells were incubated with mAbs specific for each surface marker in 50μL PBS for 30 min at RT. (29) . The absolute numbers of Treg were calculated using total white cell blood counts determined for each patient. Normal control (NC) values for the frequency and absolute Treg numbers were available in our laboratory having been determined previously.
P53 peptides and measurement of p53-specific CTL. The frequency of CTL specific for wt p53 epitopes was determined by tetramer flow cytometry. Tetramers specific for the wt p53 [149] [150] [151] [152] [153] [154] [155] [156] [157] sequences (STPPPGTRV) and wt p53 264-272 sequences (LLGRNSFEV) were obtained from the NIH tetramer facility (Atlanta, GA). The specificity of the p53 tetramers was confirmed by staining against a CTL line specific for p53 as well as irrelevant CTL. The gate for tetramer 
APM component expression in DC.
APM components TAP1, TAP2, LMP2 and tapasin were determined by flow cytometry (31, 32) . Cells were fixed in 2% paraformaldehyde for 10min at RT and permeabilized in 100% methanol for > 24h at -20˚C. Cells were then washed and incubated with primary APM component-specific mAb and FITC-conjugated secondary antimouse mAb for 30min at RT, respectively. A minimum of 100,000 events were acquired and the cut-off level was set at MFI (5) based on IgG2a isotype control.
Quantitation of tumor infiltrating lymphocytes (TIL). H&E stained sections of 11 vaccinees'
blinded tumor sections were reviewed, and the intra-tumoral infiltrating lymphocytes (TIL) were enumerated in five high power fields (400×). Tumor cells comprised at least 60% of each field.
The extent of TIL was determined by the average value of the TIL numbers in the five counted fields. As a relative measure of intratumoral inflammation, lymphocytic tumoral infiltration was considered mild, moderate, or prominent, if the TIL number was ≤ 10, 11-20, ≥ 20, respectively.
Classification of patient clinical outcome and immune responses after vaccination were evaluated for each group to identify patterns associated with extent of TIL present.
Statistics. All averages were calculated as means. Paired samples were evaluated by Wilcoxon paired signed-rank test, and correlations were calculated by the Spearman test using SPSS software (IBM, version 19). The permutation test was used for significance of T cell reactivity. 
Results

Clinical information of vaccinated patients.
Demographics of the wt p53 peptide-based DC vaccinated cohort are shown in Table 1 .
The vaccine was well tolerated by all patients, with skin rash at injection sites and circumscribed hematomas after leukapheresis in 2/16 patients, but no grade II-IV adverse events occurred. No differences were observed between vaccine arms. All patients were followed every 3 months using clinical examination and periodic PET/CT scans for 3 years.
Disease-free survival and tumor immunohistochemistry
Among the 16 vaccinated patients, 3 died of disease (DOD) at 16, 17 and 25 months; 13 patients remain alive with no evidence of disease (NED) the median follow-up of 32 months (range 6 -42 months). Thus, two-year disease-free survival (DFS) was 88% and three-year DFS was 80% ( Figure 1A ). This DFS rate was favorable, as compared to the DFS of a similar, previously untreated stage III/IV clinical trial cohort treated with chemoradiation at our institution, as published previously (70%, 95% Confidence Interval 53% -82% %, ref. (33) 
Characteristics of vDC
Monocyte-derived matured DC generated for vaccine therapy (vDC) in the HNSCC patients showed significant up-regulation of surface markers HLA-DR, CD86, CD80 and CD83
Research. relative to autologous mononuclear cells or immature (i)DC (Figure 2A) . Phenotyping was performed after peptide loading, and there were no differences in expression of surface markers between DC pulsed with class I or class II peptides; therefore, their phenotypic results are grouped in Figure 2A . After DC-1 maturation, up-regulation of CD80, CD86, and HLA-A2 was stronger, while up-regulation of CD83 and CCR7 was weaker compared to vDC. Downregulation of CD1a was greater in DC1 than in vDC (all adjusted signed rank p < .01).
APM components were also measured, and TAP1/2, LMP2 and tapasin were modestly upregulated in vDC as compared to iDC, similar to our previous findings (31) (Figure 2B) .
Expression of antigen processing machinery (APM) components (TAP1, TAP2, LMP2 and tapasin) was measured in iDC, vDC and DC1. Although we observed an increased expression of APM components in vDC and DC1 relative to iDC (p < 0.05), upregulation of APM components was again significantly stronger in DC1 than in vDC (p < 0.05, Figure 2B ). Significant differences were seen in the expression of additional surface maturation markers between DC matured in these two cocktails as shown in Figure 2C .
Peptide-specific CTL responses to the vaccine
Immune monitoring at baseline and at three post-vaccination time points included tetramer analysis for the frequency of wt p53-specific CTL ( Figure 3A) . Peptide-specific immune response was considered to be positive when the following criteria were met: (1) the frequency of p53-specific CTL was above LLD of 0.013%, as established previously (34); (2) 
determine whether wt p53 peptide-specific reactivity predicted DFS. As shown in Figure 3C , peptide-specific immune responses after vaccination did not differentiate patients based on DFS.
ELISPOT assays
The presence of IFN-γ producing CTL in patients' PBMC upon stimulation with T2 cell pulsed with the wt p53 peptides was measured in ELISPOT assays. Serial assays were performed at all 4 time points. Representative data for single tetramer-positive patients (one in each Arm) are shown in Figure 3D . The data show variably increased numbers of spots at the postvaccination time point vs. background values for four selected patients who were tetramer responders. These were the only patients among 16 tested with positive ELISPOT results.
Interestingly, positive IFN-γ responses to the wt p53 peptides as well as to the tetanus peptide were seen, suggesting epitope spreading and/or non-peptide specific activation of immune cells in these 4 patients.
Regulatory T cells (Treg) levels after vaccination
In this study, Treg were evaluated by flow cytometry and defined as CD4+CD25+CD39+
T cells, as shown in Figure 4A . We have previously reported that these Treg cells were highly In order to determine whether the overall decrease in Treg number is due to vaccinationindependent non-specific contribution of tumor-infiltrating lymphocytes (TIL), we analyzed 11available pre-vaccine tumor specimens histologically. The surgical resection preceded vaccination by 2 mo -23 mo, and these tumor specimens showed varied extent of TIL levels. 
Functional studies with HNSCC patients' DC generated by an alternative protocol
The functional characteristics of DC matured by different maturation regimens were also determined. To test this, immature DC (iDC) generated from cryopreserved CD14+ monocytes of 13/16 patients were matured by an alternative cytokine protocol. Thus, iDC were matured for 48h in the presence of the DC1 cocktail of cytokines (21), containing IFNs and polyI:C, as described in Materials and Methods. In parallel, using the same iDC, maturation was performed with the cytokine cocktail utilized for maturation of the vDC administered to patients. The peptide-pulsed vDC and DC1 were also tested for cytokine secretion (IL-10, IL-12, VEGF) by Luminex TM . As shown in Figure 5A , vDC produced more IL-10, IL-12 and VEGF than iDC; however, the ratios of IL-10/IL-12 were not different in vDC loaded with combinations of peptides and used in Arms 1 to 3 ( Figure 5B ). As shown in Figure 5A , DC1 produced more IL-12 and less IL-10 than did vDC, and only vDC produced VEGF. The data suggest that vDC have an immunosuppressive functional profile relative to DC1 which mediate stronger adjuvant effects. In Figure 5C , a significant negative correlation between IL-10 and IL-12 levels in DC1 is shown as well as a positive correlation between VEGF and IL-10 in vDC, further illustrating the cytokine profile associated with vDC. to the best of our knowledge, the largest tumor-peptide specific DC-based vaccination trial in HNSCC reported to date, and it is the first to incorporate a T helper (Th) peptide derived from the same TA, p53, while using modified/optimized HLA class I binding peptides to generate CTL. It has been previously shown that the induction of tumor-specific CTL required crosspresentation of the relevant helper peptides via class II molecules on mDC (17, 22) . Activated Nevertheless, the vaccine was apparently able to induce changes in immunoregulatory mechanisms. One consistent finding in nearly all vaccinated patients was a significant reduction in the frequency and absolute number of circulating Treg after vaccination. This decline in Treg was not restricted to the protocol arms using a class II-restricted peptide in the vaccine but occurred in nearly all vaccinated patients. In addition, the overall decrease in Treg frequency and absolute number in almost every patient in this cohort appeared to be a specific result from vaccination and unrelated to the intra-tumoral inflammation status, given the fact that the examined tumor specimens displayed a wide range of TIL levels, from as few as 6 TIL per high power field to more than 50 TIL per high power field.
As Treg are known to suppress effective anti-tumor immune responses and impair patient prognosis (42, 43) , their normalization post-vaccine could be expected to restore or upregulate anti-tumor immunity. However, despite consistently seen decline in the Treg frequency and absolute numbers after vaccination, anti-wt p53-specific responses measured by tetramer analysis or ELISPOT assays were few and weak. The role of Treg in human cancer is still controversial, and our finding implying that Treg normalization by the vaccine is not sufficient for restoration of anti-tumor immunity further highlights the uncertain role these cells seem to play in cancer progression. In contrast to our study, many DC-based vaccines have been reported to increase the frequency of circulating Treg relative to that before vaccination. This discrepancy could be in part explained by the fact that reliable surface markers controversial for human Treg. By using CD39, an ectonucleotidase, in addition to CD25 as surface markers for Treg implies that the vaccine also had an impact on the adenosine pathway, which is known to be involved in down-regulation of immune cell functions.
We acknowledge that additional immunosuppressive subsets exist in HNSCC patients, including MDSC, and with a small number of available residual specimens we were unable to detect a consistent vaccine effect on MDSC frequency in PBMC (data not shown). Further vaccine trials will clearly need to incorporate studies and disruption of these cells to permit full efficacy of vaccination, in addition to Treg reduction.
One of the key objectives of DC-based vaccination is to restore suppressed anti-tumor immunity by providing effective antigen presentation and strong adjuvant activity (31, 32) . In HNSCC patients, DC are not fully competent for T cell priming, likely due to their incomplete maturation (19, 21) . Thus, DC generation and maturation for vaccine production is a critical step.
It is clear that vDC used for therapy in this trial were not functionally optimal despite a normal surface expression of co-stimulatory and HLA molecules as evaluated by flow cytometry.
Importantly, vDC produced little IL-12 and an excess of immunoinhibitory factors, IL-10 and VEGF; they did not up-regulate expression of crucial APM components upon maturation in the presence of the conventional cytokine cocktail. The ex vivo comparison of vDC with DC1 matured in parallel from iDC of the same HNSCC patients by an alternative cytokine cocktail convincingly demonstrates that superior DC can be generated from monocytes derived from the blood of HNSCC patients using alternative maturation cocktails. Further, it has been determined that phenotypic and functional characteristics of vDC generated from patients with cancer differ from those of DC generated from normal donors (16) . Since the vaccination outcome might depend on the quality of injected vDC, it is necessary to ensure that vDC are mature and functionally effective.
Given the fact that DC generated from HNSCC patients preferentially produced IL-10 and had only mild adjuvant effects in vivo, we considered a possibility that vDC were not optimally matured. To test this hypothesis, immature DC (iDC) generated from cryopreserved CD14+ monocytes of 13/16 patients were matured by an alternative cytokine protocol. Thus, iDC were matured for 48h in the presence of the DC1 cocktail of cytokines (21), containing IFNs and polyI:C, as described in Materials and Methods. In parallel, using the same iDC, maturation was performed with the cytokine cocktail utilized for maturation of the vDC administered to alive (30) alive (29) alive (41) alive (06) DOD (17) alive ( (27) alive (42) alive (38) alive ( (25) alive (26) DOD (16) alive (39) alive (33) alive (29) CUP -cancer of unknown primary, DOD -death of disease (r) recurrent disease before vaccination
